S&P 500 Healthcare Sector SEC Filings — March 12, 2026

12-03-2026

Orrstown Financial Services reported average total assets of $5.43B in 2025, up 25.7% YoY from $4.32B, fueled by 25.2% loan growth to $3.95B average balance and net interest income expansion of 28.7% to $199.8M with NIM improving to 4.04%. Noninterest income surged 39.7% YoY to $52.3M, driven by trust/brokerage and swap fees, while noninterest expenses remained nearly flat at $149.4M (up 0.7%) due to sharply lower merger-related costs ($2.6M vs $22.7M). However, mortgage banking income declined 1.6% YoY and investment securities gains fell 33.3%.

• ·Accretion on purchase accounting marks: $21.5M in 2025 (vs $15.2M in 2024)
• ·Merger-related expenses: $2.6M in 2025 (down from $22.7M in 2024)
• ·Investment securities portfolio book value $972.1M with average maturity 23.3 years
• ·Salaries and employee benefits up 11.2% YoY to $85.2M

12-03-2026

Elicio Therapeutics reported a reduced net loss of $39.6M for the year ended December 31, 2025, improving 23.8% YoY from $51.9M, primarily due to operating expenses declining 16.2% to $37.7M, with R&D expenses dropping sharply 26.0% to $24.9M. However, G&A expenses increased 13.1% to $12.8M, cash used in operating activities remained nearly flat at $37.0M, total assets decreased to $25.9M from $28.2M, and net cash position slightly declined by $225K. Stockholders' equity improved to a positive $1.6M from a $11.3M deficit, supported by financing activities including stock issuances.

• ·Net cash provided by financing activities: $36.7M in 2025 vs $42.3M in 2024.
• ·Long-term debt, net: $9.4M at Dec 31 2025 vs $20.0M at Dec 31 2024.
• ·Warrant liabilities: $2.6M at Dec 31 2025 vs $2.8M at Dec 31 2024.
• ·Cash, cash equivalents and restricted cash: $19.3M at Dec 31 2025 vs $19.5M at Dec 31 2024.
• ·Weighted average common shares outstanding: 15,312,751 in 2025 vs 12,202,996 in 2024.
• ·Net loss per common share: $(2.58) in 2025 vs $(4.25) in 2024.

12-03-2026

CACI International Inc entered into a Second Supplemental Indenture on March 12, 2026, issuing $500 million in additional 6.375% Senior Notes due 2033, increasing the total outstanding principal to $1.5 billion. The company received net proceeds of approximately $518 million, intended for repaying revolving credit facility debt used in the ARKA Group L.P. acquisition. The notes are senior unsecured, guaranteed by subsidiaries, with no reported issues in the offering process.

• ·Interest payable semi-annually on June 15 and December 15; first payment for Additional Notes on June 15, 2026, including accrued interest from December 15, 2025.
• ·Notes mature on June 15, 2033.
• ·Issued in private placement to qualified institutional buyers under Rule 144A.
• ·Base Indenture dated June 2, 2025; First Supplemental Indenture dated November 25, 2025.

12-03-2026

Velocity Financial, Inc. filed an 8-K on March 12, 2026, disclosing under Regulation FD the posting of management's fourth quarter and full year 2025 earnings presentation on its Investor Relations website (www.velfinance.com) as of March 11, 2026. The presentation is furnished as Exhibit 99 but no specific financial metrics, improvements, or declines were detailed in the filing itself.

• ·Filing covers Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits).
• ·Securities: Common stock, par value $0.01 per share (VEL) listed on NYSE and NYSE Texas, Inc.
• ·Principal offices: 2945 Townsgate Road, Suite 110, Westlake Village, California 91361.

12-03-2026

Lennar Corporation reported Q1 2026 (ended February 28, 2026) net earnings of $229 million ($0.93 per diluted share), down sharply from $520 million ($1.96) YoY, driven by homebuilding revenues declining 13% to $6.3 billion on 5% fewer deliveries (16,863 homes) at an 8% lower average sales price ($374,000), with gross margins contracting to 15.2% from 18.7% and SG&A rising to 9.8% of home sales revenues. New orders rose 1% YoY to 18,515 homes, backlog stood at 15,588 homes valued at $6.0 billion, and Financial Services operating earnings fell to $91 million from $143 million, though Multifamily improved to $18 million and Lennar Other loss narrowed to $5 million. The company maintained strong liquidity with $2.1 billion in homebuilding cash, no borrowings under its $3.1 billion facility, and repurchased 2 million shares for $237 million.

• ·Q2 2026 guidance: New orders 21,000-22,000 homes; deliveries 20,000-21,000 homes; ASP $370,000-$375,000; gross margin 15.5%-16.0%; SG&A 8.9%-9.1%; Financial Services earnings $100M-$110M.
• ·Operational improvements: Starts pace 3.4 homes/community/month; sales pace 3.6; cycle time 122 days; inventory turn 2.5x; construction costs down 2.5% QoQ and 12% over 2 years.
• ·Effective tax rate 23.1% in Q1 2026 vs 24.6% in Q1 2025.

12-03-2026

Firefly Neuroscience, Inc. entered a securities purchase agreement on March 8, 2026, to issue up to 13,500,000 units at $1.50 per unit, with an initial closing on March 12, 2026, for 1,500,000 units raising $2.25M from accredited investors. Investors have the option for up to $18M additional investment within 30 days, including shares or pre-funded warrants plus 5-year warrants at $1.88 and $2.50 exercise prices, subject to 4.99%/9.99% beneficial ownership limits and lock-up agreements through March 12, 2027. The private placement complies with Nasdaq rules without shareholder approval, with an S-1 registration statement due by April 15, 2026.

• ·Private placement exempt under Section 4(a)(2) and Rule 506(b) of Regulation D.
• ·Lock-Up Period: 6 months ending September 12, 2026; Leak-Out Period: 6 months ending March 12, 2027.
• ·S-1 Registration Statement to be filed by April 15, 2026, with effectiveness targeted within 45-90 days.
• ·Complies with Nasdaq Listing Rule 5635(d) without stockholder approval.

12-03-2026

Glacier Bancorp, Inc. (GBCI) issued its DEF 14A proxy statement dated March 12, 2026, for the Annual Meeting on April 29, 2026, proposing the election of 10 directors, an advisory vote on executive compensation, and ratification of Forvis Mazars, LLP as independent auditors for the fiscal year ending December 31, 2026. As of the record date February 26, 2026, there were approximately 130,107,508 shares of common stock outstanding. Principal shareholders as of December 31, 2025, include BlackRock, Inc. (14,183,609 shares, 10.9%) and The Vanguard Group, Inc. (12,350,033 shares, 9.5%).

• ·Annual Meeting location: The Hilton Garden Inn, 1840 Highway 93 South, Kalispell, Montana, at 9:00 a.m. Mountain Time.
• ·Proxy solicitation deadline: 11:59 p.m. Eastern Time on April 28, 2026.
• ·Subsidiary divisions include Altabank, First State Bank, Bank of the San Juans, and others.

12-03-2026

Acacia Research Corporation reported total revenues of $285.2M for 2025, surging 133% YoY from $122.3M, fueled by paid-up license revenue growth of 346% to $76.9M and industrial operations revenues up 30% to $63.8M, leading to a net income turnaround to $21.7M from a $36.1M loss in 2024. Production volumes increased 24% YoY to 2.1M Boe with gains across oil (+24%), natural gas (+25%), and NGLs (+23%). However, recurring license revenues declined 34% to $1.5M, oil prices dropped 13% to $63.02/Bbl, NGL prices fell 6%, and total costs/expenses rose 80% to $278.8M.

• ·New license agreements executed decreased to 6 from 9 (-33%).
• ·Inventor royalties increased 895% to $17.2M.
• ·Parent general and administrative expenses declined 19% to $24.7M.
• ·Cost of revenues - industrial operations slightly down 3% to $14.5M.

12-03-2026

BRC Group Holdings, Inc. announced transactions resulting in the retirement of approximately $37.9 million in outstanding debt through bond-for-equity exchanges of 1,343,551 senior note units for 4,201,300 shares of common stock and cash repurchases of 171,703 units of 5.0% senior notes for $4.0 million, with a final transaction closing March 13, 2026. The company will redeem $96 million of 5.50% Senior Notes due 2026 (RILYK) on March 30, 2026, further reducing net debt beyond preliminary year-end 2025 estimates. However, due to a new auditor onboarding in September 2025 and recent 10-Q filings, the company will file a Form 12b-25 by March 17, 2026, extending the 2025 Annual Report (10-K) deadline to March 31, 2026.

• ·Transactions conducted with long-time institutional investor pursuant to Section 3(a)(9) of the Securities Act of 1933
• ·Three Quarterly Reports on Form 10-Q filed between November 20, 2025, and January 14, 2026
• ·Q4 and Full Year 2025 Financial Results and earnings call to be announced next week, with release by March 31, 2026

12-03-2026

Stryker Corporation provided an update on an ongoing cybersecurity incident affecting its Microsoft environment, first identified on March 11, 2026, which continues to disrupt global operations including order processing, manufacturing, and shipping as of March 12, 2026. Patient-related services have not been disrupted, and connected products were unaffected. The investigation is ongoing, with the full scope, nature, and operational/financial impacts still unknown.

• ·Incident first reported on March 11, 2026
• ·Update provided on March 12, 2026 to customers and cybersecurity community

12-03-2026

Xenetic Biosciences, Inc. (XBIO) filed its 10-K on March 12, 2026, outlining extensive risks including an ongoing strategic review process by the Board and a special independent committee, with potential disruptions and no guarantee of strategic alternatives. The company emphasizes its lack of profitability, dependence on DNase technology success, need for substantial additional funding to continue as a going concern, and risks of Nasdaq delisting. Additional concerns include clinical trial delays, IP protection failures, competition, and reliance on third-party collaborators.

• ·Filing date: March 12, 2026
• ·Risk of failure to meet Nasdaq continued listing requirements
• ·Never achieved profitability and may never sustain it

12-03-2026

For the three months ended January 31, 2026, Tianci International reported total operating revenues of $3.9M, up 87% YoY driven by new mineral sales ($1.3M) and 22% growth in global logistics services, with gross profit rising 13% to $90K. However, operating expenses surged 172% to $507K primarily due to higher G&A, resulting in an operating loss of $417K (vs $106K prior) and net loss attributable to the company of $400K; for the six months, revenues grew 52% to $7.7M but net loss widened to $668K amid $1.7M cash used in operations. Total assets declined 15% to $2.7M from July 31, 2025, with cash dropping 70% to $723K.

• ·Series B Preferred Stock fully converted to 8M common shares during the period.
• ·Common shares issued for inventory purchase: 800,000 shares valued at $288K.
• ·Non-controlling interest turned negative to $(15K) from $2.6K as of July 31, 2025.
• ·Accumulated deficit increased to $(3.5M) from $(2.9M) as of July 31, 2025.

12-03-2026

Artificial Intelligence Technology Solutions Inc. completed a 100-for-1 reverse stock split processed by FINRA on March 12, 2026, after which its Board of Directors unanimously voted not to proceed with a proposed Authorized Share Increase of 3.8B common shares filed via Definitive Information Statement on March 2, 2026. The authorized capitalization remains unchanged at 27.52B total shares, including 27.5B common shares and 20M preferred shares. No other material changes or performance metrics were reported.

• ·Reverse Stock Split ratio of 100 for 1 processed by FINRA on March 12, 2026

12-03-2026

NewMarket Corporation's DEF 14A proxy statement outlines the 2026 Annual Meeting of Shareholders on April 23, 2026, seeking votes to elect seven director nominees, including newly appointed Bruce R. Hazelgrove III following Bruce C. Gottwald's retirement on December 9, 2025, ratify PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026, and approve executive compensation on an advisory basis (say-on-pay). As of the record date February 24, 2026, 9,395,455 shares of common stock were outstanding, with each share entitled to one vote. No period-over-period financial performance data or compensation metrics are detailed in the provided filing content.

• ·Annual Meeting details: Thursday, April 23, 2026 at 10:00 a.m. EDT, The Foundry Building, 500 Tredegar St., Richmond, Virginia 23219.
• ·Record date: close of business on February 24, 2026.
• ·Proxy materials available via Internet; paper copies orderable by April 13, 2026.
• ·Bruce R. Hazelgrove, III appointed to Board effective February 26, 2026, and to the Executive Committee.
• ·Voting requirements: majority of votes cast for director elections, ratification of auditor, and say-on-pay; abstentions and broker non-votes generally have no effect.

12-03-2026

Solid Biosciences Inc. announced positive interim data from the Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for Duchenne muscular dystrophy as of February 23, 2026 data cutoff, with 40 participants dosed and the therapy generally well-tolerated using a steroid-only regimen. Key results include robust microdystrophin expression (mean 60% by western blot at Day 90, 91% at Day 360), restored beta-sarcoglycan (60-69%) and nNOS activity (33-35%), plus biomarker reductions indicating improved muscle integrity (e.g., 38% CK, 43% ALT at Day 90). The company aligned with FDA on Phase 3 IMPACT DUCHENNE design, with first dosing anticipated in Q1 2026 and further updates mid-2026.

• ·Trial conducted at 15 sites across United States, Canada, Italy, and United Kingdom; dosing ongoing.
• ·FDA alignment on Phase 3 design announced February 9, 2026; participant screening underway; additional FDA meetings planned H1 2026.
• ·Updated corporate presentation made available on company website March 11, 2026.
• ·Baselines for western blot and mass spectrometry: 0% mean normal dystrophin.

12-03-2026

CITIZENS FINANCIAL SERVICES INC (CZFS) reported net interest income of $99.1M (tax-equivalent basis) for 2025, up 13.3% from $87.4M in 2024, supported by a 3.2% increase in total interest income to $159.2M and a 9.9% decline in interest expense to $61.2M. Total assets grew 1.2% to $3.04B, with average loans up 0.9% to $2.31B driven by commercial loan growth. However, average construction loans fell 25.6% to $135.9M due to project completions, reducing related interest income by $3.9M, while residential mortgage loans declined modestly.

• ·Average yield on construction loans decreased from 7.45% in 2024 to 7.17% in 2025.
• ·Commercial loan growth primarily from completed construction projects converting to permanent financing.
• ·Net interest margin (TE) improved to 3.50% in 2025 from 3.13% in 2024.

12-03-2026

CION Investment Corp's total investments at fair value decreased 4.0% YoY to $1.81B as of December 31, 2025 from $1.89B, driven by a 12.3% decline in senior secured first lien debt to $1.37B (80.8% of portfolio) while equity investments grew 31.5% to $315M (18.5%). Investment income fell 4.6% to $241M and gross portfolio yield dropped to 9.15% from 10.96%, resulting in a net decrease in net assets of $21M versus a $34M increase in 2024, amid higher realized and unrealized losses. The number of portfolio companies reduced to 89 from 105, though average portfolio company EBITDA rose to $59.1M from $53.6M.

• ·Stock traded at average discount to NAV of ~30% in 2025 quarters, worsening from ~25% in 2024.
• ·Quarterly distributions stable at $0.36 per share in 2025 (up from mix of $0.34-$0.41 in 2024).
• ·Total estimated annual expenses 19.08% of average net assets, including 11.68% interest on borrowed funds.
• ·Net portfolio activity: net sales of $104M in 2025 vs $22M in 2024.

12-03-2026

For the year ended December 31, 2025, New ERA Energy & Digital, Inc. reported net revenues of $885,400, up 66.2% YoY from $532,780 in 2024, primarily driven by higher natural gas net sales. However, a massive $12.1M impairment expense led to total costs and expenses surging 91.4% to $25.4M, while interest expense ballooned 530% to $4.8M; as a result, the net loss more than doubled to $29.6M from $13.8M. General and administrative expenses remained essentially flat at -0.1% YoY.

• ·Natural gas gross sales $2.5M in 2025 (up from $1.3M in 2024); NGL revenues declined to $240K from $254K; Oil revenues dropped to $0 from $27K.
• ·Loss from operations worsened 92.4% to $24.5M from $12.7M.
• ·Total other income (expenses) deteriorated 1,052.1% to $5.1M loss from $0.4M loss, driven by higher interest expense and new losses on debt extinguishment ($577K) and JV investment ($119K).

12-03-2026

News Corporation disclosed updates related to its $1B stock repurchase program via an 8-K filing, including information provided to the Australian Securities Exchange (ASX) attached as Exhibits 99.1 and 99.2 for daily transaction disclosures, if any. The program authorizes repurchases of up to $1B in aggregate of Class A (NWSA) and Class B (NWS) common stock. No specific repurchase transactions or volumes were detailed in the filing.

• ·Filing date: March 12, 2026; Earliest event date: March 11, 2026
• ·Securities: Class A Common Stock (NWSA, Nasdaq Global Select Market), Class B Common Stock (NWS, Nasdaq Global Select Market)

12-03-2026

12-03-2026

On March 9, 2026, the Board of Directors of Eco Science Solutions, Inc. and shareholders representing 64.57% of the voting power approved a 1-for-25 reverse stock split of the company's outstanding common stock. The company will file an Information Statement on Schedule 14C to provide notice and details of the reverse stock split.

• ·Shareholder consent dated March 9, 2026, based on voting power as of March 10, 2026.
• ·Reverse stock split ratio: 1 for 25.

12-03-2026

Beneficient appointed Mack H. Hicks, CEO of Hicks Holdings LLC and experienced private equity executive, to its Board of Directors on March 12, 2026, to continue the legacy of his late father Thomas O. Hicks, former Chairman. Separately, the company amended a prior credit agreement with a Hicks affiliate on March 10, 2026, settling approximately $1.66M in remaining accrued interest, fees, and expenses via $572,588 in Class A common stock and deferred cash payments of $94,365 (due March 31, 2026) and $1M (due September 30, 2026), enhancing near-term financial flexibility and liquidity preservation. No declines or flat metrics reported.

• ·Original credit agreement dated October 19, 2023
• ·Amendment to credit agreement dated March 10, 2026
• ·Thomas O. Hicks passed away in December 2025
• ·Hicks serves on boards of Standard Industrial Manufacturing, Bucked Up, Face Haus, Vayner Sports, and Accresa Health
• ·Hicks holds BA from University of Texas at Austin and completed Harvard Owner/President Management Program

12-03-2026

Harvard Bioscience reported Q4 2025 revenues of $23.7M, down 3.6% YoY from $24.6M despite improved gross margin of 59.7% (up 260bps) and Adjusted EBITDA of $3.8M (up 26.7% YoY). Full-year 2025 revenues declined 8.0% YoY to $86.6M from $94.1M, with gross margin slightly down to 57.7% and net loss widening to $56.7M primarily due to $48.0M goodwill impairment, though Adjusted EBITDA increased 12.5% to $8.1M. The company appointed Mark Frost as permanent CFO and guided FY2026 revenue growth of 2-4% with Adjusted EBITDA growth of 6-10%.

• ·Q1 2026 guidance: Revenues $20.0-22.0M, Adjusted gross margin 57-59%, Adjusted EBITDA $1.0-2.2M.
• ·Cash from operations Q4 2025: ($0.1M) vs $1.7M prior year.
• ·Total assets Dec 31, 2025: $80.1M vs $126.6M Dec 31, 2024.
• ·Debt refinancing costs: $1.8M in FY 2025.
• ·Loss on pension settlement: $1.2M in FY 2025.

12-03-2026

Esquire Financial Holdings, Inc. entered into a Merger Agreement on March 11, 2026, with Signature Bancorporation, Inc., involving a merger of Esquire Merger Sub into Signature followed by Signature into Esquire, and a bank merger of Signature Bank into Esquire Bank. Signature shareholders will receive 2.630 shares of Esquire common stock per Signature share (adjustable from 2.50 to 2.80 based on loan dispositions), with no cash consideration mentioned beyond fractional shares. The deal includes board expansions by two directors (Michael O’Rourke and Leonard Caronia) and integration of Signature executives, subject to customary approvals and a $15.0M termination fee payable by Signature in certain cases.

• ·Exchange ratio fixed at 2.630 shares of Esquire Common Stock per Signature Common Stock share, adjustable to max 2.80 or min 2.50 based on proceeds from Signature Bank loan dispositions.
• ·Signature stock options to be assumed by Esquire, adjusted by exchange ratio.
• ·Required approvals include Federal Reserve, OCC, Illinois Department of Financial and Professional Regulation; no materially burdensome conditions allowed.
• ·Voting agreements executed with Signature directors and executive officers.

12-03-2026

O’Reilly Automotive, Inc. issued and sold $850M aggregate principal amount of 5.100% Senior Notes due March 12, 2036, on March 12, 2026, governed by a Seventh Supplemental Indenture with U.S. Bank Trust Company, National Association. The Notes are general unsecured senior obligations, pari passu with existing senior notes series, bearing semi-annual interest starting September 12, 2026, with optional redemption features and change of control repurchase rights at 101%. No subsidiary guarantees initially, but future guarantees may apply under certain conditions.

• ·Par Call Date: December 12, 2035; redeemable thereafter at 100% of principal.
• ·Pre-Par Call redemption at greater of Treasury Rate +15 bps discounted value or 100% of principal.
• ·Indenture covenants limit liens, sale-leasebacks, and mergers; standard events of default apply.
• ·Shelf registration effective April 1, 2025 (File No. 333-286320).

12-03-2026

MVB Financial Corp's average total assets declined to $3.26B in 2025 from $3.28B in 2024 and $3.36B in 2023, with average earning assets down 1.3% YoY to $2.96B and total loans decreasing 1.8% YoY to $2.17B. Net interest income fell 1.6% YoY to $107.4M with NIM nearly flat at 3.63% versus 3.64%, though book value per share rose 11.2% to $26.26 and efficiency ratio improved to 72.8% from 80.4%. Nonperforming loans increased 24.6% to $30.7M (1.3% of loans) from $24.6M, with allowance coverage dropping to 71.2% from 79.9%.

• ·Net loan charge-offs to total loans increased to 0.26% in 2025 from 0.20% in 2024.
• ·Equity to assets improved to 10.1% in 2025 from 9.8% in 2024.
• ·Community Bank Leverage Ratio slightly declined to 11.1% in 2025 from 11.2% in 2024.
• ·Nonperforming assets stable at 0.9% of total assets in both 2025 and 2024.

12-03-2026

Kingsway Financial Services Inc reported a net loss of $10.3M in 2025, widening from $8.3M in 2024, driven by an 80% plunge in Extended Warranty segment operating income to $1.2M from $5.9M, despite KSX segment operating income rising 38% to $7.8M from $5.7M amid acquisitions. Total segment operating income declined 23% to $8.9M, with higher G&A expenses ($11.0M), interest ($5.4M), and amortization ($8.2M) offsetting gains in net investment income (+14% to $1.6M) and reduced impairments. The overall loss from continuing operations worsened to $10.3M from $8.1M.

• ·Image Solutions acquired effective September 26, 2024, contributing $2.0M operating income in 2025.
• ·Roundhouse acquired July 1, 2025, with $9.7M revenue and $2.0M operating income.
• ·Kingsway Skilled Trades recorded $10.3M revenue and $0.2M operating loss post-acquisitions of Bud's Plumbing (March 2025) and Advanced/Southside Plumbing (August 2025).
• ·DDI operating income increased to $1.2M in 2025.
• ·Ravix operating income decreased to $2.4M due to 19% revenue drop.
• ·Income tax benefit included $1.2M (2025 vs $0.2M 2024) from interest/NOL and $2.7M (2025 vs -$0.1M 2024) from deferred tax valuation allowance change.

12-03-2026

Cassava Sciences Inc. (SAVA) filed its 10-K on March 12, 2026, outlining extensive risks including a full clinical hold by the FDA on planned simufilam studies, no approved products, heavy dependence on simufilam for TSC-related epilepsy, and significant net losses since inception with no product revenues. The company faces challenges in clinical development, manufacturing reliance on third parties, regulatory approval uncertainties, and ongoing capital needs amid stock price volatility. All forward-looking aspects, from trial timelines to commercialization, are flagged with substantial uncertainties and potential delays.

• ·FDA has placed a full clinical hold on planned clinical studies.
• ·No history of product approvals for commercial sale.
• ·Reliance on third-party contractors for all clinical and non-clinical trials and drug supply.

12-03-2026

CIMG Inc. filed an 8-K on March 12, 2026, under Items 5.03 and 9.01, disclosing amendments to its charter or bylaws, with related exhibits attached. The company, a miscellaneous retail firm incorporated in Nevada with fiscal year end September 30 and operations based in Hong Kong, has a history of name changes from Havana Furnishings Inc. and NuZee, Inc. No financial metrics or performance data were reported in this filing.

• ·Filing CIK: 0001527613
• ·SIC: 5900 - RETAIL-MISCELLANEOUS RETAIL
• ·State of Incorporation: NV
• ·Fiscal Year End: September 30
• ·Business Address: ROOM R2, FTY D, 16/F, KIN GA IND. BLDG. 9 SAN ON STREET, TUEN MUN HONG KONG
• ·Phone: (760) 295-2408

12-03-2026

Supplemental proxy materials for the proposed reorganization of abrdn National Municipal Income Fund (VFL) into MFS Municipal Income Trust (MFM), which broadens VFL's investment mandate by removing the 20% limit on High Yield municipal bonds, allowing for 30-50% allocation compared to VFL's current 19% High Yield exposure versus MFM's 40%. The change aims to enhance income, support higher distributions, improve diversification, and achieve better risk-adjusted returns through access to a larger universe of higher-yielding bonds. While presenting modest increase in credit risk, management highlights benefits like lower expenses, larger fund size, and stronger long-term performance.

• ·VFL credit quality (12/31/25): AAA 2%, AA 45%, A 15%, BBB 21%, BB 2%, B 2%, CCC and below 1%, Not Rated 14%
• ·MFM credit quality (12/31/25): AAA 1%, AA 16%, A 23%, BBB 21%, BB 11%, B 3%, CCC and below 1%, Not Rated 25%
• ·Aberdeen's track record shows 0 defaults from 2017-2025 in Muni Suite compared to Bloomberg Muni Universe

12-03-2026

Greenland Mines Ltd (formerly Klotho Neurosciences, Inc., NASDAQ: GRML) completed the acquisition of Greenland Mines on March 4, 2026, for convertible preferred equity (conversion subject to shareholder approval), creating two divisions: Natural Resources (Skaergaard Project) and Cell and Gene Therapy. The Skaergaard Project holds 13.2 Moz AuEq resources valued at $68B in-situ (Feb 2026 prices), ranking 11th globally among undeveloped deposits, with plans to double to 26.4 Moz AuEq or ~50M oz contained Au, Pd, Pt via new drilling. Name and ticker change effective March 12, 2026; investor presentation webcast held same day.

• ·Skaergaard Project ranks 11th globally among undeveloped gold deposits by AuEq value (13.2 Moz)
• ·80% ownership with option to acquire remaining 20%
• ·Greenland Mines management joins team with one new Board Member
• ·Trading symbols: Common Stock (KLTO/GRML), Warrants (KLTOW)

12-03-2026

Citizens, Inc. reported consolidated revenues of $255.6M for the year ended December 31, 2025, up 4% YoY from $245.0M, supported by higher net investment income (+3%) and other income (+54%), though life insurance premiums grew only 2% and accident & health premiums declined 1%. Income before federal income taxes increased 17% to $17.5M, driven by exceptional Domestic segment performance (+534% to $12.1M), but offset by a sharp 39% decline in the International segment to $14.4M and ongoing losses in Other Non-Insurance Enterprises (improved to $(9.0)M from $(10.4)M). Total invested assets grew 3% to $1.5B.

• ·Fixed maturity securities comprised 87.9% of invested assets at Dec 31, 2025 (up from 86.0% in 2024), with corporate bonds at 59.2%.
• ·Other Non-Insurance Enterprises loss improved 13% YoY to $(9.0)M from $(10.4)M.
• ·Municipal bonds totaled $268.8M at Dec 31, 2025 (18.3% of invested assets).

12-03-2026

MBX Biosciences reported Q4 and FY 2025 financial results with pro forma cash and investments of $459.1M as of Dec 31, 2025 (including $85.4M net proceeds from ATM), expected to fund operations into 2029, alongside pipeline progress such as Phase 3 canvuparatide trial initiation on track for Q3 2026 and MBX 4291 Phase 1 data in Q4 2026. However, net losses widened to $22.1M in Q4 2025 (+42% YoY) and $87.0M for FY 2025 (+41% YoY), driven by R&D expenses rising to $19.8M in Q4 (+30% YoY) and $79.2M FY (+38% YoY), and G&A to $6.0M Q4 (+77% YoY) and $18.9M FY (+75% YoY). Corporate highlights include board appointment of Laurie Stelzer and hiring of Karen Basbaum as Chief Business Officer.

• ·EU Orphan Drug Designation granted for canvuparatide.
• ·Working capital Dec 31, 2025: $366.0M (vs $256.2M Dec 31, 2024).
• ·Total stockholders’ equity Dec 31, 2025: $369.2M (vs $257.4M Dec 31, 2024).

12-03-2026

Enodia Therapeutics acquired Kezar Life Sciences' preclinical Sec61-based discovery and development assets for an upfront payment of $1 million and potential future milestone payments totaling up to $127 million, plus tiered royalties on net sales. The deal strengthens Enodia's Sec61 selectivity insights and accelerates development of its small-molecule inhibitors for targeted protein degradation in inflammation, immunology, oncology, and virology. Kezar, after nearly ten years of pioneering research, views Enodia as well-positioned to advance the program while focusing on its lead candidate zetomipzomib for autoimmune diseases.

• ·Filing Date: March 12, 2026
• ·SEC Items: 1.01 (Entry into Material Definitive Agreement), 2.01 (Completion of Acquisition), 7.01 (Regulation FD Disclosure), 9.01 (Financial Statements)
• ·Kezar's Sec61 research spanned nearly ten years

12-03-2026

Montauk Renewables, Inc. reported audited consolidated financial results for the year ended December 31, 2025, with revenue up slightly 0.4% YoY to $176.4M and net asset value per share increasing 2.8% to $1.84. However, EBITDA declined sharply 21.2% to $32.3M, headline earnings fell 60.4% to $4.4M, and earnings per share dropped 85.7% to $0.01. The board resolved not to declare a final dividend to prioritize operational development.

• ·Headline earnings per common share: $0.03 in 2025 vs $0.08 in 2024 (-62.5%)
• ·Gross impairment of plant and equipment: $3.231M in 2025 (net $2.582M) vs $1.586M in 2024 (net $1.268M)
• ·Loss on disposal of plant and equipment: $36K gross in 2025 (net $28K)
• ·Common shares outstanding as of Dec 31, 2025: as reported in Form 10-K filed March 11, 2026

12-03-2026

Pfizer's 2026 proxy statement highlights 2025 total revenues of $62.6B, reflecting a 2% YoY operational decline from $63.6B, while revenues excluding COVID-19 products grew 6% operationally. The company advanced cost savings with $600M realized by year-end 2025 toward a $5.7B target by end-2026, returned $9.8B to shareholders via dividends, and invested $10.4B in R&D and $8.8B in business development including the Metsera acquisition. Strategic initiatives like Accord for a Healthier World reached nearly 800,000 patients, a fourfold increase YoY.

• ·Cost realignment program first phase manufacturing optimization on track for $1.5B net savings by end-2027.
• ·Pfizer operates 13 U.S. manufacturing facilities, producing 45B doses of 500+ medicines/vaccines for 200 countries/territories annually.

12-03-2026

UMB Financial Corporation's DEF 14A proxy statement, dated March 12, 2026, solicits votes for the virtual 2026 annual shareholder meeting on April 28, 2026, including election of 14 directors for terms ending in 2027, an advisory say-on-pay vote on 2025 named executive officer compensation, ratification of KPMG LLP as independent auditors for 2026, and approval of the Amended and Restated Omnibus Incentive Compensation Plan. As of the February 27, 2026 record date, 76,136,588 shares of $1.00 par value common stock were outstanding and eligible to vote. The filing discloses corporate governance practices, 2025 director and executive compensation details (via tables including Summary Compensation Table and Pay vs. Performance), and no material related-party transactions since January 1, 2025.

• ·Virtual annual meeting at 9:00 a.m. CDT; access via www.meetnow.global/MGTKNHR.
• ·Beneficial owners must register legal proxy by April 22, 2026, 5:00 p.m. ET for participation.
• ·No delinquent Section 16 reports noted.
• ·No material related-party transactions since January 1, 2025.